Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Narro GEC, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Among authors: cusi k. Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24. Ann Hepatol. 2024. PMID: 37364816 Free article. Review.
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.
Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri BA, Cusi K, Loomba R, Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. Mak LY, et al. Among authors: cusi k. J Hepatol. 2023 Apr;78(4):684-692. doi: 10.1016/j.jhep.2022.11.025. Epub 2022 Dec 10. J Hepatol. 2023. PMID: 36513186 Clinical Trial.
A multistakeholder approach to innovations in NAFLD care.
Schattenberg JM, Allen AM, Jarvis H, Zelber-Sagi S, Cusi K, Dillon JF, Caussy C, Francque SM, Younossi Z, Alkhouri N, Lazarus JV. Schattenberg JM, et al. Among authors: cusi k. Commun Med (Lond). 2023 Jan 3;3(1):1. doi: 10.1038/s43856-022-00228-y. Commun Med (Lond). 2023. PMID: 36596859 Free PMC article.
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice.
Lazarus JV, Castera L, Mark HE, Allen AM, Adams LA, Anstee QM, Arrese M, Alqahtani SA, Bugianesi E, Colombo M, Cusi K, Hagström H, Loomba R, Romero-Gómez M, Schattenberg JM, Thiele M, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Francque SM, Tsochatzis EA. Lazarus JV, et al. Among authors: cusi k. JHEP Rep. 2022 Sep 22;5(1):100596. doi: 10.1016/j.jhepr.2022.100596. eCollection 2023 Jan. JHEP Rep. 2022. PMID: 36644239 Free PMC article.
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Sanyal AJ, Munoz B, Cusi K, Barritt AS 4th, Muthiah M, Mospan AR, Reddy KR, Firpi-Morell R, Thuluvath PJ, Bhamidimarri KR, Fried MW; TARGET-NASH Investigators. Sanyal AJ, et al. Among authors: cusi k. Clin Gastroenterol Hepatol. 2023 Oct;21(11):2889-2900.e10. doi: 10.1016/j.cgh.2023.02.024. Epub 2023 Mar 5. Clin Gastroenterol Hepatol. 2023. PMID: 36871772
Research Priorities for Precision Medicine in NAFLD.
Iruzubieta P, Bataller R, Arias-Loste MT, Arrese M, Calleja JL, Castro-Narro G, Cusi K, Dillon JF, Martínez-Chantar ML, Mateo M, Pérez A, Rinella ME, Romero-Gómez M, Schattenberg JM, Zelber-Sagi S, Crespo J, Lazarus JV. Iruzubieta P, et al. Among authors: cusi k. Clin Liver Dis. 2023 May;27(2):535-551. doi: 10.1016/j.cld.2023.01.016. Epub 2023 Feb 26. Clin Liver Dis. 2023. PMID: 37024222 Review.
A global research priority agenda to advance public health responses to fatty liver disease.
Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Hagström H, Huang TT, Wajcman DI, Kautz A, Kopka CJ, Krag A, Miller V, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM; Healthy Livers, Healthy Lives Collaborators. Lazarus JV, et al. Among authors: cusi k. J Hepatol. 2023 Sep;79(3):618-634. doi: 10.1016/j.jhep.2023.04.035. Epub 2023 Jun 20. J Hepatol. 2023. PMID: 37353401 Free article.
248 results